Xalud Therapeutics is a gene therapy company developing novel therapies for the treatment of neuro-inflammatory diseases and inflammatory joint disorders including osteoarthritis and rheumatoid arthritis. Immune activation is a hallmark of multiple diseases. IL-10 gene therapy is effective in reversing immune activation and pain in multiple animal models and across platforms.

Xalud’s lead product candidate, XT-150, harnesses the power of the body’s potent natural anti-inflammatory protein, IL-10, to treat inflammatory diseases of the central nervous system (CNS) and joints. It’s currently undergoing two phase 2 trials for the treatment of osteoarthritis pain.


Founded 2011
Partnered 2015